Publication: Cardiac effects of antimalarial treatment with halofantrine
Issued Date
1993-04-24
Resource Type
ISSN
01406736
Other identifier(s)
2-s2.0-0027404778
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
The Lancet. Vol.341, No.8852 (1993), 1054-1056
Suggested Citation
F. Nosten, F. O. ter Kuile, C. Luxemburger, C. Woodrow, T. Chongsuphajaisiddhi, N. J. White, D. E. Kyle Cardiac effects of antimalarial treatment with halofantrine. The Lancet. Vol.341, No.8852 (1993), 1054-1056. doi:10.1016/0140-6736(93)92412-M Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/22728
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Cardiac effects of antimalarial treatment with halofantrine
Abstract
In a prospective electrocardiographic study of Karen patients with acute uncomplicated falciparum malaria, mefloquine (25 mg/kg) had no cardiac effects (n=53), but halofantrine (72 mg/kg) induced consistent dose-related lengthening of the PR and QT intervals in all 61 patients treated. The likelihood of significant QTc prolongation (by more than 25% or a QTc of 0·55 s1/2or more) was greater after halofantrine as retreatment following mefloquine failure than as primary treatment (7/10 vs 18/51; relative risk 2·0 [95% Cl 1·1-3·4], p = 0·04). More than 60% of the effect occurred with three doses of halofantrine (24 mg/kg). The arrhythmogenic potential of halofantrine should now be investigated. © 1993.